Literature DB >> 11833055

Association between hyperinsulinemia and endogenous androgen levels in peri- and postmenopausal women.

Maria Augusta Maturana1, Poli Mara Spritzer.   

Abstract

We evaluated the relationship between hyperinsulinemia and anthropometric, metabolic, and hormonal parameters that might contribute to the risk for coronary heart disease (CHD) in 104 peri- and postmenopausal women. Plasma glucose, insulin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), sex hormone-binding globulin (SHBG), and total testosterone (TT) were determined. Free androgen index (FAI) and fasting insulin to glucose ratio (IGR) were calculated. The cut off point to define hyperinsulinemia was established at 23 microIU/mg. Mean age was 54.8 years. Mean age at menopause was 47.7 years. Body mass index (BMI) was greater than 25 in 46 patients, and 28 (26.9%) were hyperinsulinemic. BMI, waist circumference, triglycerides, and 2-hour postglucose insulin levels were significantly higher in hyperinsulinemic patients. Hyperinsulinemic patients had higher TT levels (P =.02), FAI (P =.0001), and lower SHBG levels (P =.003). Positive correlations were observed between IGR and BMI, waist-to-hip ratio (WHR), waist circumference, and triglycerides. IGR and high-density lipoprotein-cholesterol (HDL-C) were negatively correlated. IGR presented a positive association with TT and FAI and a negative association with SHBG. FAI contributed positively to IGR, independently of BMI, age, or time since menopause. In conclusion, androgen levels may be important determinants of risk factors for cardiovascular diseases in peri- and postmenopausal women. However, this observation should be confirmed by longitudinal studies. Copyright 2002 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11833055     DOI: 10.1053/meta.2002.29997

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopause.

Authors:  A Tufano; P Marzo; R Enrini; L Morricone; F Caviezel; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

2.  Smoking as a determinant for plasma levels of testosterone, androstenedione, and DHEAs in postmenopausal women.

Authors:  Jonas Manjer; Robert Johansson; Per Lenner
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

3.  Clinical pharmacology and vascular risk.

Authors:  G Silvestrelli; F Corea; S Micheli; A Lanari
Journal:  Open Neurol J       Date:  2010-06-15

Review 4.  Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention.

Authors:  K P Morgan; A Kapur; K J Beatt
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

5.  Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease.

Authors:  Shrita M Patel; Sarah J Ratcliffe; Muredach P Reilly; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; Kim Sutton-Tyrrell; John Robbins; Linda P Fried; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2009-10-21       Impact factor: 5.958

6.  Androgenicity and venous endothelial function in post-menopausal women.

Authors:  M A Maturana; M C Rubira; F Consolim-Colombo; M C Irigoyen; P M Spritzer
Journal:  J Endocrinol Invest       Date:  2009-10-09       Impact factor: 4.256

7.  Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.

Authors:  Emma Hazelwood; Eleanor Sanderson; Vanessa Y Tan; Katherine S Ruth; Timothy M Frayling; Niki Dimou; Marc J Gunter; Laure Dossus; Claire Newton; Neil Ryan; Dimitri J Pournaras; Tracy A O'Mara; George Davey Smith; Richard M Martin; James Yarmolinsky
Journal:  BMC Med       Date:  2022-04-19       Impact factor: 11.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.